Pravastatin

證據等級: L5

預測適應症: 9 個

One-Sentence Summary

Pravastatin is an HMG-CoA reductase inhibitor (statin); the evidence base consistently describes it as a treatment for hypercholesterolemia/dyslipidemia, though formal original-indication and MOA records are flagged as data gaps in this pack. Of 9 TxGNN-predicted indications screened for this candidate, HIV-related dyslipidemia / cardiovascular risk management emerged as the most clinically credible, supported by 16 clinical trials (including dedicated Phase 2–4 RCTs of pravastatin in HIV-infected patients) and 20 publications. This is risk-factor management in HIV patients on antiretroviral therapy, not an antiviral effect.

Quick Overview

Item	Content
Original Indication	Not available in source data (`taiwan_regulatory.licenses` is empty). Trial/literature descriptions in this evidence base consistently identify pravastatin as an HMG-CoA reductase inhibitor for hypercholesterolemia/dyslipidemia.
Predicted New Indication	HIV infectious disease (ART-related dyslipidemia / cardiovascular risk management)
TxGNN Prediction Score	99.74% (rank 3562)
Evidence Level	L2
Germany Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

All Predicted Indications Screened (for transparency)

Rank	Disease	TxGNN Score	Evidence Level	Decision	Note
1	Homozygous familial hypercholesterolemia	99.95%	L4	Hold	Statin efficacy limited by non-functional LDLR in HoFH
2	HIV infectious disease	99.74%	L2	Proceed with Guardrails	Selected as primary candidate (see below)
3	Neurodevelopmental disorder (ataxic gait/absent speech)	99.62%	L5	Hold	No trials, no literature, no mechanistic rationale
4	Feline acquired immunodeficiency syndrome	99.55%	L5	Hold	Veterinary disease; graph spill-over via HIV homology
5	Simian immunodeficiency virus infection	99.55%	L5	Hold	Primate model virus; no human evidence
6	Familial hypercholesterolemia	99.34%	L1	Proceed with Guardrails	Already an established statin indication, not a novel repurposing candidate
7	Hypoalphalipoproteinemia	99.21%	L4	Hold	No dedicated trials; statin effect on HDL is modest/off-target
8	Hypercholesterolemia due to CYP7A1 deficiency	99.07%	L5	Hold	Ultra-rare disease; mechanistic speculation only
9	Cholesterol-ester transfer protein deficiency	99.04%	L5	Hold	No mechanistic or clinical link to statin pathway

Why is This Prediction Reasonable?

The original_moa field itself is marked as a data gap, but the underlying evidence base repeatedly and consistently identifies pravastatin as a competitive HMG-CoA reductase inhibitor that lowers hepatic cholesterol synthesis and upregulates LDL receptor expression (e.g., PMID 1658544, NCT00227500). This mechanism is the pharmacological basis for its use in hypercholesterolemia/dyslipidemia.

HIV infection and its antiretroviral therapy (ART), particularly protease-inhibitor-based regimens, are well documented in this evidence base to cause dyslipidemia, chronic immune activation, and accelerated atherosclerosis, substantially raising cardiovascular risk in people living with HIV. Statins are therefore a rational adjunct in this population — not as antiviral agents, but as lipid-lowering and potentially anti-inflammatory/immunomodulatory therapy addressing a major ART-related comorbidity.

Pravastatin specifically stands out among statins for this population because it is not extensively metabolized via CYP3A4, unlike atorvastatin or simvastatin, reducing the risk of clinically significant drug-drug interactions with protease inhibitors and other ART agents that are strong CYP3A4 inhibitors. This DDI advantage is explicitly the rationale behind multiple dedicated trials in this evidence pack (e.g., NCT00000941, NCT00630734, NCT00117494) that established pravastatin as a preferred statin choice for HIV-infected, PI-treated patients with dyslipidemia.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00006412	Phase 3	Completed	630	Fenofibrate vs. pravastatin in HIV-infected subjects with lipid abnormalities
NCT00117494	Phase 4	Completed	86	Rosuvastatin vs. pravastatin in ART-treated dyslipidemic HIV patients (ANRS 126)
NCT00221754	Phase 2	Completed	21	RCT of pravastatin in hypercholesterolemic HIV patients on protease inhibitors
NCT00147797	N/A	Completed	84	Pravastatin effect on carotid artery structure/function in HIV patients on ART
NCT00227500	Phase 4	Completed	40	Randomized, double-blind, placebo-controlled pravastatin trial in HIV hyperlipidaemia
NCT00000941	Phase 1	Completed	56	PK interactions between protease inhibitors and statins (pravastatin, simvastatin, atorvastatin)
NCT02841774	Phase 2	Completed	10	HILLCLIMBER: moderate-dose pravastatin vs. high-dose rosuvastatin in HIV patients with CHD
NCT00630734	Phase 4	Completed	32	SLCO1B1 genetic predictors of darunavir/ritonavir–pravastatin DDI
NCT00982189	N/A	Completed	37	Cardiovascular risk-reduction polypill pilot in HIV-infected persons
NCT00843661	Phase 4	Unknown	60	Ezetimibe+fenofibrate vs. pravastatin monotherapy in HIV patients on protease inhibitors

Literature Evidence

PMID	Year	Type	Journal	Key Findings
28416195	2017	RCT (Phase 4)	The Lancet HIV	INTREPID trial: pitavastatin vs. pravastatin in HIV-1 patients with dyslipidaemia, avoiding CYP450-dependent metabolism
25574964	2014	RCT	AIDS	Atorvastatin reduced T-cell activation; pravastatin had no significant immune-activation effect
26148680	2015	RCT, cross-over	BMC Research Notes	Pravastatin, phytosterols, and combination therapy compared for lipid-lowering in HIV
28252528	2017	Cohort/RCT	AIDS	Pitavastatin and pravastatin compared on immune activation and arterial inflammation markers in HIV
16603852	2006	RCT (placebo-controlled)	AIDS	Pravastatin effect on body composition and cardiovascular markers in HIV-infected men
17117030	2006	Cohort	AIDS	Pravastatin had no significant influence on carotid intima-media thickness or aortic stiffness in HIV patients
16218799	2005	RCT	AIDS Research and Human Retroviruses	ACTG 5087: fenofibrate vs. pravastatin for combined dyslipidemia in HIV
18991624	2008	Review	Current HIV Research	Comparative review of rosuvastatin, pravastatin, and atorvastatin for PI-associated hypercholesterolaemia
28364370	2017	Review/Guideline	American Journal of Cardiovascular Drugs	Recommendations for managing statin–HIV medication drug-drug interactions
25907504	2015	Systematic Review	The American Journal of Cardiology	Systematic review of statin therapy usefulness in HIV-infected patients

Germany Market Information

No marketing authorizations are currently on file for this candidate (total_licenses: 0, market status: Not Marketed). No product/dosage-form/indication details are available to summarize.

Safety Considerations

Formal safety fields (key warnings, contraindications, DDI database) are all empty or data gaps in this pack, and no TFDA/BfArM label has been retrieved yet (see DG001, Blocking).

Drug interactions noted in trial evidence (not from a formal DDI database):

Pravastatin is repeatedly used as a low-CYP3A4-dependency statin in probe-substrate DDI studies (NCT04425902, NCT02578277), and its PK is affected by OATP1B1/SLCO1B1 transporter variants when co-administered with darunavir/ritonavir (NCT00630734) and raltegravir (NCT00665717) — relevant specifically to the HIV indication under review.

For all other safety information, please refer to the package insert once available.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple dedicated Phase 2–4 RCTs (including a 630-patient Phase 3 trial) establish pravastatin's efficacy and DDI-favorable profile for managing ART-related dyslipidemia and cardiovascular risk in HIV-infected patients — a genuine, evidence-supported repurposing signal distinct from pravastatin's already-established statin indications (e.g., familial hypercholesterolemia, rank 6, which is not novel). The remaining 7 of 9 TxGNN predictions (L4–L5) lack sufficient clinical or mechanistic support and are held.

To proceed, the following is needed:

Official product label / warnings and contraindications (DG001, Blocking — TFDA/BfArM PDF retrieval)
Confirmed mechanism-of-action documentation (DG002 — DrugBank query)
Formal DDI database query specific to ART regimens (protease inhibitors, integrase inhibitors)
Clarification of target population and endpoint (ART-associated dyslipidemia/CV risk reduction, not antiviral effect)
Assessment of German/EU marketing-authorization pathway, given current "Not Marketed" status
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.